GSK plc

NYSE:GSK Stock Report

Market Cap: US$70.6b

GSK Future Growth

Future criteria checks 4/6

GSK is forecast to grow earnings and revenue by 22.4% and 3.9% per annum respectively. EPS is expected to grow by 22.1% per annum. Return on equity is forecast to be 28.7% in 3 years.

Key information

22.4%

Earnings growth rate

22.1%

EPS growth rate

Pharmaceuticals earnings growth24.0%
Revenue growth rate3.9%
Future return on equity28.7%
Analyst coverage

Good

Last updated13 Nov 2024

Recent future growth updates

No updates

Recent updates

GSK Q3 Earnings Preview: Shingrix And Arexvy Make The Stock A 'Strong Buy'

Oct 26

GSK's Q2 Success Amid Challenges: What Investors Need To Know

Aug 26

GSK: Good Earnings Report, But Risks Ahead (Rating Downgrade)

Jul 31

GSK Breathes New Life Into Asthma Treatment With Depemokimab

May 22

Earnings and Revenue Growth Forecasts

NYSE:GSK - Analysts future estimates and past financials data (GBP Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202634,3386,4876,4899,53716
12/31/202532,4515,8025,6158,48317
12/31/202431,2713,5443,9626,61717
9/30/202431,3112,5114,9177,421N/A
6/30/202431,4464,0335,2227,479N/A
3/31/202430,7404,4845,3307,673N/A
12/31/202330,3284,9284,4366,768N/A
9/30/202329,6526,0783,2475,477N/A
6/30/202329,3345,3732,4864,586N/A
3/31/202329,0854,4552,8924,914N/A
12/31/202229,3244,4615,3417,403N/A
9/30/202229,0243,3877,6209,265N/A
6/30/202227,8223,5058,07310,506N/A
3/31/202226,7314,0137,61110,163N/A
12/31/202124,6963,3165,9397,952N/A
9/30/202126,3593,5676,0648,040N/A
6/30/202128,3783,9344,8716,339N/A
3/31/202130,1644,9837,0287,807N/A
12/31/202024,3544,8736,8398,441N/A
9/30/202034,2596,3716,8338,039N/A
6/30/202034,9986,6798,7519,693N/A
3/31/202035,1835,3806,6288,322N/A
12/31/201933,7544,6456,2618,020N/A
9/30/201933,0524,5616,8328,686N/A
6/30/201931,7594,4276,4888,248N/A
3/31/201931,2603,9046,7358,221N/A
12/31/201830,8213,6236,8818,421N/A
9/30/201830,2631,8625,5217,171N/A
6/30/201830,0141,656N/A6,991N/A
3/31/201830,0241,035N/A6,637N/A
12/31/201730,1861,532N/A6,918N/A
9/30/201730,1332,335N/A7,040N/A
6/30/201729,8321,931N/A6,910N/A
3/31/201729,0441,676N/A7,138N/A
12/31/201627,889912N/A6,497N/A
9/30/201626,589301N/A5,007N/A
6/30/201625,17431N/A3,721N/A
3/31/201624,530615N/A2,702N/A
12/31/201523,9238,422N/A2,569N/A
9/30/201523,8239,809N/A3,278N/A
6/30/201523,3429,672N/A4,070N/A
3/31/201523,01510,177N/A4,619N/A
12/31/201423,0062,756N/A5,176N/A
9/30/201423,7264,184N/A5,153N/A
6/30/201424,5904,752N/A5,957N/A
3/31/201425,6475,143N/A6,902N/A
12/31/201326,5055,436N/A7,222N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: GSK's forecast earnings growth (22.4% per year) is above the savings rate (2.6%).

Earnings vs Market: GSK's earnings (22.4% per year) are forecast to grow faster than the US market (15.5% per year).

High Growth Earnings: GSK's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: GSK's revenue (3.9% per year) is forecast to grow slower than the US market (8.9% per year).

High Growth Revenue: GSK's revenue (3.9% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: GSK's Return on Equity is forecast to be high in 3 years time (28.7%)

Discover growth companies

7D

1Y

7D

1Y

7D

1Y